H.C. Wainwright raised Palvella Therapeutics’ price target to $255 from $200, maintaining a Buy rating. Phase 3 SELVA data showed a statistically significant 2.13-point mean change, a “clear and decisive win” according to the analyst. If approved, the efficacy demonstrated in the trial is expected to lead to strong patient uptake. Source: TheFly.

For more information on PVLA, visit Disclaimer & Disclosure or Report an Issue.

Read more at Yahoo Finance: Palvella Therapeutics price target raised to $255 from $200 at H.C. Wainwright